The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | CRITICS-II: comparing neoadjuvant chemo, chemoradiotherapy, and surgery in gastric cancer
Marcel Verheij, MD, PhD, Radboud University Medical Centre, Nijmegen, Netherlands, discusses the results of the CRITICS-II study, a multicenter randomized Phase II trial of neoadjuvant chemotherapy followed by surgery versus neoadjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neoadjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
